Prescrire Int. 2008 Jun;17(95):109.
In HIV-infected patients with multiple antiretroviral treatment failure, two trials show that adding darunavir + ritonavir to optimised antiretroviral treatment is more effective than adding other protease inhibitors. Clinical trials, involving relatively few patients, revealed no significant adverse effects that had not previously been seen with HIV protease inhibitors. There is a high risk of drug interactions with darunavir.
在接受多种抗逆转录病毒治疗失败的HIV感染患者中，两项试验表明，在优化的抗逆转录病毒治疗方案中加用达芦那韦+利托那韦比加用其他蛋白酶抑制剂更有效。涉及患者相对较少的临床试验显示，未发现此前使用HIV蛋白酶抑制剂时未曾出现的显著不良反应。达芦那韦存在较高的药物相互作用风险。
